<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39354270</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1868-601X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Translational stroke research</Title><ISOAbbreviation>Transl Stroke Res</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 Spike Protein Exacerbates Thromboembolic Cerebrovascular Complications in Humanized ACE2 Mouse Model.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12975-024-01301-5</ELocationID><Abstract><AbstractText>COVID-19 increases the risk for acute ischemic stroke, yet the molecular mechanisms are unclear and remain unresolved medical challenges. We hypothesize that the SARS-CoV-2 spike protein exacerbates stroke and cerebrovascular complications by increasing coagulation and decreasing fibrinolysis by disrupting the renin-angiotensin-aldosterone system (RAAS). A thromboembolic model was induced in humanized ACE2 knock-in mice after one week of SARS-CoV-2 spike protein injection. hACE2 mice were treated with Losartan, an angiotensin receptor (AT<sub>1</sub>R) blocker, immediately after spike protein injection. Cerebral blood flow and infarct size were compared between groups. Vascular-contributes to cognitive impairments and dementia was assessed using a Novel object recognition test. Tissue factor-III and plasminogen activator inhibitor-1 were measured using immunoblotting to assess coagulation and fibrinolysis. Human brain microvascular endothelial cells (HBMEC) were exposed to hypoxia with/without SARS-CoV-2 spike protein to mimic ischemic conditions and assessed for inflammation, RAAS balance, coagulation, and fibrinolysis. Our results showed that the SARS-CoV-2 spike protein caused an imbalance in the RAAS that increased the inflammatory signal and decreased the RAAS protective arm. SARS-CoV-2 spike protein increased coagulation and decreased fibrinolysis when coincident with ischemic insult, which was accompanied by a decrease in cerebral blood flow, an increase in neuronal death, and a decline in cognitive function. Losartan treatment restored RAAS balance and reduced spike protein-induced effects. SARS-CoV-2 spike protein exacerbates inflammation and hypercoagulation, leading to increased neurovascular damage and cognitive dysfunction. However, the AT<sub>1</sub>R blocker, Losartan, restored the RAAS balance and reduced COVID-19-induced thromboembolic cerebrovascular complications.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heath</LastName><ForeName>Stan P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, School of Medicine, Mercer University, Savannah, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermanns</LastName><ForeName>Veronica C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, School of Medicine, Mercer University, Savannah, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coucha</LastName><ForeName>Maha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, South University, Savannah, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelsaid</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9846-6623</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, School of Medicine, Mercer University, Savannah, GA, USA. Abdelsaid_ma@mercer.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Department, Mercer University School of Medicine, 1250 E 66th Street | Savannah, 31404, Macon, GA, United States. Abdelsaid_ma@mercer.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>23AIREA1045073 to MA</GrantID><Agency>American Heart Association</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Stroke Res</MedlineTA><NlmUniqueID>101517297</NlmUniqueID><ISSNLinking>1868-4483</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19-induced Thromboembolic Complications</Keyword><Keyword MajorTopicYN="N">RAAS Balance</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 Spike Protein</Keyword><Keyword MajorTopicYN="N">Vascular-contributes to Cognitive Impairments and Dementia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>23</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39354270</ArticleId><ArticleId IdType="doi">10.1007/s12975-024-01301-5</ArticleId><ArticleId IdType="pii">10.1007/s12975-024-01301-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kempuraj D, et al. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist. 2020;26(5–6):402–14.</Citation><ArticleIdList><ArticleId IdType="pubmed">32684080</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiotakopoulos L, et al. Use of an additional updated 2023–2024 COVID-19 vaccine dose for adults aged &gt;/=65 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(16):377–81.</Citation><ArticleIdList><ArticleId IdType="pubmed">38662708</ArticleId><ArticleId IdType="pmc">11065461</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related stroke. Transl Stroke Res. 2020;11(3):322–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">32378030</ArticleId><ArticleId IdType="pmc">7202903</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett FN, et al. SARS-CoV-2 spike protein intensifies cerebrovascular complications in diabetic hACE2 mice through RAAS and TLR signaling activation. Int J Mol Sci. 2023;24(22):16394.</Citation><ArticleIdList><ArticleId IdType="pubmed">38003584</ArticleId><ArticleId IdType="pmc">10671133</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagnazzo F, et al. Neurological manifestations of patients infected with the SARS-CoV-2: a systematic review of the literature. J Neurol. 2021;268(8):2656–65.</Citation><ArticleIdList><ArticleId IdType="pubmed">33125542</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma A, et al. Stroke and thromboprophylaxis in the era of COVID-19. J Stroke Cerebrovasc Dis. 2021;30(1): 105392.</Citation><ArticleIdList><ArticleId IdType="pubmed">33130478</ArticleId></ArticleIdList></Reference><Reference><Citation>Aceti A, et al. Serum S100B protein as a marker of severity in Covid-19 patients. Sci Rep. 2020;10(1):18665.</Citation><ArticleIdList><ArticleId IdType="pubmed">33122776</ArticleId><ArticleId IdType="pmc">7596559</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank MG, et al. SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: evidence of PAMP-like properties. Brain Behav Immun. 2022;100:267–77.</Citation><ArticleIdList><ArticleId IdType="pubmed">34915155</ArticleId></ArticleIdList></Reference><Reference><Citation>Holter JC, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci U S A. 2020;117(40):25018–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">32943538</ArticleId><ArticleId IdType="pmc">7547220</ArticleId></ArticleIdList></Reference><Reference><Citation>Portier I, Campbell RA, Denorme F. Mechanisms of immunothrombosis in COVID-19. Curr Opin Hematol. 2021;28(6):445–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">34232139</ArticleId><ArticleId IdType="pmc">8490282</ArticleId></ArticleIdList></Reference><Reference><Citation>De Michele M, et al. SARS-CoV-2 infection predicts larger infarct volume in patients with acute ischemic stroke. Front Cardiovasc Med. 2022;9:1097229.</Citation><ArticleIdList><ArticleId IdType="pubmed">36704480</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshafei A, et al. RAAS, ACE2 and COVID-19; a mechanistic review. Saudi J Biol Sci. 2021;28(11):6465–70.</Citation><ArticleIdList><ArticleId IdType="pubmed">34305426</ArticleId><ArticleId IdType="pmc">8270731</ArticleId></ArticleIdList></Reference><Reference><Citation>den Molina-Van M, et al. [The renin-angiotensin system and the brain]. Hipertens Riesgo Vasc. 2021;38(3):125–32.</Citation></Reference><Reference><Citation>Kutz A, et al. Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19. Eur J Endocrinol. 2021;184(4):543–52.</Citation><ArticleIdList><ArticleId IdType="pubmed">33539316</ArticleId><ArticleId IdType="pmc">9494311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekholm M, Kahan T. The impact of the renin-angiotensin-aldosterone system on inflammation, coagulation, and atherothrombotic complications, and to aggravated COVID-19. Front Pharmacol. 2021;12: 640185.</Citation><ArticleIdList><ArticleId IdType="pubmed">34220496</ArticleId><ArticleId IdType="pmc">8245685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96(5):2515–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">7593643</ArticleId><ArticleId IdType="pmc">185912</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292(1):C82-97.</Citation><ArticleIdList><ArticleId IdType="pubmed">16870827</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckenstaler R, et al. Angiotensin II receptor type 1 - an update on structure, expression and pathology. Biochem Pharmacol. 2021;192: 114673.</Citation><ArticleIdList><ArticleId IdType="pubmed">34252409</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M, et al. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation. 1992;85(1):305–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">1728462</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelletti P, et al. From cardiovascular system to brain, the potential protective role of mas receptors in COVID-19 infection. Eur J Pharmacol. 2023;959: 176061.</Citation><ArticleIdList><ArticleId IdType="pubmed">37775018</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P, Sriramula S, Lazartigues E. ACE2/ANG-(1–7)/Mas pathway in the brain: the axis of good. Am J Physiol Regul Integr Comp Physiol. 2011;300(4):R804-17.</Citation><ArticleIdList><ArticleId IdType="pubmed">21178125</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirbhate E, et al. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. Pharmacol Rep. 2021;73(6):1539–50.</Citation><ArticleIdList><ArticleId IdType="pubmed">34176080</ArticleId><ArticleId IdType="pmc">8236094</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutsch A, Schunkert H. RAAS inhibition and beyond-cardiovascular medications in patients at risk of or affected by COVID-19. Herz. 2023;48(3):206–11.</Citation><ArticleIdList><ArticleId IdType="pubmed">37097476</ArticleId><ArticleId IdType="pmc">10127983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuster GM, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19):1801–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32196087</ArticleId><ArticleId IdType="pmc">7184407</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, et al. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020;12(1):69.</Citation><ArticleIdList><ArticleId IdType="pubmed">32498691</ArticleId><ArticleId IdType="pmc">7271826</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X, et al. The effects of ATIR Blocker on the severity of COVID-19 in hypertensive inpatients and virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic mice. J Cardiovasc Transl Res. 2022;15(1):38–48.</Citation><ArticleIdList><ArticleId IdType="pubmed">34973134</ArticleId><ArticleId IdType="pmc">8720170</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature. 2021;592(7852):122–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33636719</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier M, et al. Timing matters in the use of renin-angiotensin system modulators and COVID-related cognitive and cerebrovascular dysfunction. PLoS ONE. 2024;19(7): e0304135.</Citation><ArticleIdList><ArticleId IdType="pubmed">39074114</ArticleId><ArticleId IdType="pmc">11285960</ArticleId></ArticleIdList></Reference><Reference><Citation>Culman J, et al. Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important? Naunyn Schmiedebergs Arch Pharmacol. 2017;390(9):949–59.</Citation><ArticleIdList><ArticleId IdType="pubmed">28669009</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe PG, et al. Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer’s disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2021;20(11):895–906.</Citation><ArticleIdList><ArticleId IdType="pubmed">34687634</ArticleId><ArticleId IdType="pmc">8528717</ArticleId></ArticleIdList></Reference><Reference><Citation>Coucha M, et al. Inhibition of Ephrin-B2 in brain pericytes decreases cerebral pathological neovascularization in diabetic rats. PLoS ONE. 2019;14(1): e0210523.</Citation><ArticleIdList><ArticleId IdType="pubmed">30620753</ArticleId><ArticleId IdType="pmc">6324788</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardigan T, et al. Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in type 2 diabetes. Am J Physiol Regul Integr Comp Physiol. 2016;311(3):R466-77.</Citation><ArticleIdList><ArticleId IdType="pubmed">27357799</ArticleId><ArticleId IdType="pmc">5142225</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, et al. Stroke increases the expression of ACE2, the SARS-CoV-2 binding receptor, in murine lungs. Brain Behav Immun. 2021;94:458–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">33621620</ArticleId><ArticleId IdType="pmc">7896496</ArticleId></ArticleIdList></Reference><Reference><Citation>Anrather J, Iadecola C. Inflammation and stroke: an overview. Neurotherapeutics. 2016;13(4):661–70.</Citation><ArticleIdList><ArticleId IdType="pubmed">27730544</ArticleId><ArticleId IdType="pmc">5081118</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonneville R, Dangayach NS, Newcombe V. Neurological complications of critically ill COVID-19 patients. Curr Opin Crit Care. 2023;29(2):61–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">36880556</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau VI, et al. Non-COVID outcomes associated with the coronavirus disease-2019 (COVID-19) pandemic effects study (COPES): a systematic review and meta-analysis. PLoS ONE. 2022;17(6): e0269871.</Citation><ArticleIdList><ArticleId IdType="pubmed">35749400</ArticleId><ArticleId IdType="pmc">9231780</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlovic T, et al. Predicting attitudinal and behavioral responses to COVID-19 pandemic using machine learning. PNAS Nexus. 2022;1(3):pgac093.</Citation><ArticleIdList><ArticleId IdType="pubmed">35990802</ArticleId><ArticleId IdType="pmc">9381137</ArticleId></ArticleIdList></Reference><Reference><Citation>Molaverdi G, et al. Neurological complications after COVID-19: a narrative review. eNeurologicalSci. 2023;33: 100485.</Citation><ArticleIdList><ArticleId IdType="pubmed">38077923</ArticleId><ArticleId IdType="pmc">10700397</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung JM, et al. New directions in infection-Associated ischemic stroke. J Clin Neurol. 2024;20(2):140.</Citation><ArticleIdList><ArticleId IdType="pubmed">38330416</ArticleId><ArticleId IdType="pmc">10921058</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M. COVID and the brain: researchers zero in on how damage occurs. Nature. 2021;595(7868):484–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">34234323</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners S, Kehoe PG, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res Ther. 2020;12(1):170.</Citation><ArticleIdList><ArticleId IdType="pubmed">33380345</ArticleId><ArticleId IdType="pmc">7772800</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinjikji W et al. Endotheliitis and cytokine storm as a mechanism of clot formation in COVID-19 ischemic stroke patients: A histopathologic study of retrieved clots. Interv Neuroradiol. 2023;15910199231185804.</Citation></Reference><Reference><Citation>Amruta N et al. Mouse adapted SARS-CoV-2 (MA10) viral infection induces Neuroinflammation in Standard Laboratory Mice. Viruses. 2022;15(1):114.</Citation></Reference><Reference><Citation>Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006;113(5):722–31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461845</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuya H, et al. PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity. Sci Rep. 2022;12(1):12186.</Citation><ArticleIdList><ArticleId IdType="pubmed">35842542</ArticleId><ArticleId IdType="pmc">9288475</ArticleId></ArticleIdList></Reference><Reference><Citation>Juneja GK, et al. Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: a single-center prospective longitudinal study. J Thromb Haemost. 2021;19(6):1546–57.</Citation><ArticleIdList><ArticleId IdType="pubmed">33826233</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrader J, et al. [Effects of long-term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study)]. Med Klin (Munich). 2008;103(7):491–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18604484</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Hirayama T, Hasegawa Y. Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke. J Stroke Cerebrovasc Dis. 2007;16(5):225–31.</Citation><ArticleIdList><ArticleId IdType="pubmed">17845921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed HA, et al. RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial. J Neuroinflammation. 2018;15(1):229.</Citation><ArticleIdList><ArticleId IdType="pubmed">30103772</ArticleId><ArticleId IdType="pmc">6090822</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>